The current guideline recommends to give antithrombotic treatment 24 hours after intravenous thrombolysis in acute ischemic stroke. However, early neurological deterioration will occur in some patients due to no antithrombotic treatment, which is closely associated with poor outcome. The current trial aims to investigate the effectiveness and safety of early antithrombotic treatment after intravenous thrombolysis in minor stroke.

Inclusion Criteria:

• Age ≥ 18 years old;
• Acute ischemic stroke patients who received intravenous thrombolysis within 4.5 hours of onset;
• NIHSS ≤ 5 within 6 hours after the end of intravenous thrombolysis, and no bleeding transformation was found in head CT examination;
• Premorbid mRS ≤ 1;
• Signed informed consent.

Exclusion Criteria:

• Premorbid mRS≥2;
• Uncontrolled severe hypertension (systolic pressure >180 mmHg or diastolic pressure >110 mmHg after drug treatment);
• Antithrombotic treatment within 24 hours before randomization;
• Significant dysphagia and inability to take the experimental drug orally;
• Allergy or contraindication to study drugs;
• Comorbidity with any serious diseases and life expectancy is less than half a year;
• Participating in other clinical trials within three months;
• Patients not suitable for this clinical study considered by researcher